Indeed it did:
Edit:
Wedbush holder fast pÄ OUTPERFORM med $47 12 mÄneders price target:
https://equities.wedbush.com/clientsite/Research/ActionAlertFilePreview.asp?UUID=02396215-FC33-44BB-B163-FA3F3FAEBEE0&ViewerID=98725308-D6C0-4761-B138-61F084CB3D82
Veldig nice, gratulerer! 
Teller ikke pengene enda. 
men det var digg Ä fÄ en bounce.
Ser ikke helt ohs, vil du utdype?
Ahus er forresten indikasjonen OMS721 nÄ skal i fase 3 for:
https://twitter.com/hashtag/ahus?src=hash
IBB surrer rett over 1000 dagers snitt
Kanskje litt far-fetched nÄr jeg tenker meg om men noe sÄnn:
Venstre skulder rundt 14.
Hode rundt 9.
HÞyre skulder dannes nÄ - brudd opp gjennom 12.50-14.00 utlÞser formasjonen?
Hmm, joa. Eneste mÄtte vÊre at jeg ikke tror det er noen helt umiddelbare triggere som kan utlÞse et sÄnt legg oppover.
Omeros to Present Results from Dose-Ranging Stage of OMS721 Clinical Trial in Atypical Hemolytic Uremic Syndrome at World Congress of Nephrology
http://investor.omeros.com/phoenix.zhtml?c=219263&p=irol-newsArticle_Print&ID=2256515
Seven patients with aHUS were enrolled in Stage 1: three patients in the low-dose group, two patients in the mid-dose group and two patients in the high-dose group. One patient in the high-dose group was PT-responsive and the remaining six patients were PT-resistant. The data demonstrate a dose response in platelet count assessed as change from baseline. The mean change from baseline in platelet count was statistically significant (p < 0.05) as measured by area under the curve (AUC). Renal replacement therapy (RRT) was able to be discontinued in one patient during OMS721 treatment and renal function remained stable following completion of treatment. Another patient, who was on chronic RRT and considered ineligible for kidney transplantation, stabilized on OMS721 treatment and was deemed eligible for transplantation.
âThese data demonstrate a clear dose response with significant and clinically meaningful improvement in aHUS patients treated with OMS721,â stated Professor Nowicki. âNot only was platelet count increased with just four weeks of dosing in these patients, renal failure was reversed and dialysis was able to be stopped. Assuming that similar data are seen in the ongoing Phase 3 trial, OMS721 would represent an important and welcome treatment for patients with aHUS.â
OMS721 was well tolerated in this trial. Five serious adverse events (SAEs) were reported. A case of granulomatous orchitis in a patient with a prior history of M. haemophilum infection was considered by the investigator to be possibly a relapse and treatment-related; all cultures were subsequently found to be negative and the patient recovered. No other SAEs were considered treatment-related.
âOur Phase 3 trial evaluating OMS721 in aHUS patients is underway,â stated Gregory A. Demopulos, M.D., chairman and chief executive officer of Omeros. âOMS721 has been shown to ablate activity in the lectin pathway of complement, believed to be the trigger for aHUS, and we expect that patients will find subcutaneous dosing of OMS721 both convenient and comfortable. In addition to our Phase 3 program in aHUS, we are planning to initiate Phase 3 programs this year in IgA nephropathy and in stem cell transplant-associated thrombotic microangiopathy, and the breadth of potential indications for OMS721 continues to grow.â
Fasiten for OMER viser en nydelig dag, med grunnlag i et lovende abstract.
Tilfeldigvis falt det sammen med dagen vi fikk golden cross.
Say what? 
Hihi. This is biotech, plutselig kommer den forlÞsende meldingen. Vi fÄr se om der fortsetter i kveld. Men i gÄr var sjette eller sjuende dagen pÄ rad OMER var blandt de sterkeste biotechene jeg har pÄ watch list og det er ikke sÄ fÄ.
Oioioi, fortsetter Ă„ komme drypp fra OMER:
Pasient som ikke kunne behandles med dagens standardlegemiddel Soliris (https://en.wikipedia.org/wiki/Eculizumab) ble reddet av OMS721.
Title: Omeros Announces OMS721 Presentation at Annual Meeting of the European Society for Blood and Marrow Transplantation
Date(s): 28-Mar-2017 7:01 AM
â Additional Positive âChallenge-Rechallengeâ Data Reported in Patient with Stem Cell Transplant-Associated TMA â
SEATTLEâ(BUSINESS WIRE)âMar. 28, 2017-- Omeros Corporation (NASDAQ: OMER) today announced presentation of a case report describing resolution of hematopoietic stem cell transplant-associated thrombotic microangiopathy (HSCT-TMA) in a dialysis- and transfusion-dependent adolescent girl who was treated with OMS721 under a compassionate-use protocol. The presentation âResolution of acute kidney injury secondary to TA-TMA by the anti-MASP-2 monoclonal antibody OMS721 in a pediatric HSCT recipientâ occurred at the 43rd Annual Meeting of the European Society for Blood and Marrow Transplantation in Marseille, France on Monday, March 27, 2017. Marco Zecca, M.D., Director of Pediatric Oncology at the Fondazione IRCCS Policlinico San Matteo, presented the data. OMS721 is Omerosâ lead human monoclonal antibody targeting mannan-binding lectin-associated serine protease-2 (MASP-2), the effector enzyme of the lectin pathway of the complement system.
The presentation describes a girl who developed HSCT-TMA following stem cell transplantation at 14 years of age. She was initially treated with eculizumab but did not tolerate treatment, developing pulmonary edema that recurred on retreatment with eculizumab. The HSCT-TMA became life-threatening and she required hemodialysis and daily platelet transfusions. Dr. Zecca, the patientâs physician, requested OMS721 for compassionate-use treatment and Omeros complied. Following OMS721 treatment, the patient was able to discontinue hemodialysis and to decrease substantially her platelet transfusion requirements. Recently, the patientâs dose of OMS721 was tapered, but she developed a viral infection that reactivated her HSCT-TMA. Her TMA was again successfully treated with restoration of the original OMS721 dose. To date, she has remained free of both dialysis and transfusions.
âThis patient had severe TMA that I believe would have caused her death,â stated Dr. Zecca. âHer positive response to OMS721 treatment, both initially and following her virus-induced relapse during tapering, was impressive - the results of OMS721 treatment in this challenge-rechallenge scenario underscore the important effects of the drug. Since the poster was produced, her TMA has remained in remission and we have been able to discontinue her platelet transfusions. Her rapid response has been heartening, and we all are grateful for this remarkable outcome.â
Thrombotic microangiopathy is a potentially life-threatening complication of HSCT. Approximately 20,000 HSCT procedures are performed in the U.S. annually, and TMA is reported to occur in up to 30 percent of HSCT patients. Although the kidney is the most commonly affected organ, HSCT-TMA is a multi-system disorder and can also manifest clinically in the lungs, gastrointestinal tract and central nervous system. Reported mortality in patients with multi-organ involvement is greater than 90%. Even in patients who survive acute episodes, HSCT-TMA increases the risk for chronic kidney disease and end-stage renal disease.
----------------------------------------------------------------------â
âI say this with humility, we are saving livesâ sitat deres CEO denne mĂ„neden.
Smekket forbi motstanden pÄ 13 pÄ meningsfullt volum! 
Dette er blandt de tyngst shortede aksjene pÄ bÞrsen der borte, sÄ det kan bli litt koko.
16,1⊠fytti katta!
Edit: 16,4 og 52 week high ja.
Ja det var et voldsomt hopp den gjorde der, men synes alltid sÄnne overdrevne bevegelser skaper mest stÞy
SprÞ avslutning pÄ Diffusion der!
Aldri hĂžrt om det selskapet
Jeg kjenner lite til selskapet selv, men den dukket opp i Nasdaq-lista mi etter nesten 4-gangeren intradag i januar.
Biotekens Dryships! 
NĂ„ kommer det spennende for Omeros, blir det nok en gang en dud opptur?
Er noen ting som taler for at det kan gÄ annerledes denne gangen, men biotech.
